Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Biological Chemistry

Editor-in-Chief: Brüne, Bernhard

Editorial Board: Buchner, Johannes / Lei, Ming / Ludwig, Stephan / Thomas, Douglas D. / Turk, Boris / Wittinghofer, Alfred


IMPACT FACTOR 2018: 3.014
5-year IMPACT FACTOR: 3.162

CiteScore 2018: 3.09

SCImago Journal Rank (SJR) 2018: 1.482
Source Normalized Impact per Paper (SNIP) 2018: 0.820

Online
ISSN
1437-4315
See all formats and pricing
More options …
Volume 383, Issue 10

Issues

NF-κB A Potential Therapeutic Target for Inhibition of Human Cytomegalovirus (Re)activation?

S. Prösch / R. Wuttke / D. H. Krüger / H.-D. Volk
Published Online: 2005-06-01 | DOI: https://doi.org/10.1515/BC.2002.181

Abstract

From clinical studies the proinflammatory cytokine TNFα was proposed to play a key role in human cytomegalovirus (HCMV) reactivation from latency. In vitro experiments confirmed that TNFα stimulates the activity of the HCMV IE1/2 enhancer/promoter, which controls immediate early protein IE1 and IE2 gene expression via activation of the transcription factor NFκB and its binding to putative binding sites in the IE1/2 enhancer. NFκB was also proposed to be involved in IE1-mediated autostimulation of this promoter. The IE1/2 enhancer of HCMV contains four putative NFκB binding sites which differ in their distance to the transcription start site as well as in their sequence. Construction and testing of a series of promoter mutants demonstrated that NFκB is essential for both TNFα and IE1 stimulation. Furthermore, we were able to show that although all four NFκB sites bind NFκB with similar affinity in vitro, the contribution to TNFα and IE1 stimulation differs in correlation with the distance to the transcription start site and the sequence. Site 1 and 3 play the most dominant role and site 2 an intermediate, while site 4, which is conserved in sequence but far distant from the transcription start site, had no influence on NFκBmediated regulation of the IE1/2 promoter. Specific inhibition of NFκB signalling by coexpression of a dominantnegative IκB variant reduced TNFα stimulation of the IE1/2 enhancer/promoter by up to 80%. From this data, inhibitors of NFκB activation are suggested to be an alternative therapeutical strategy to interfere with HCMV (re)activation in undifferentiated monocyte/granulocyte progenitor cells in patients with a high risk of inflammationrelated HCMV (re)activation.

About the article

Published Online: 2005-06-01

Published in Print: 2002-10-06


Citation Information: Biological Chemistry, Volume 383, Issue 10, Pages 1601–1609, ISSN (Print) 1431-6730, DOI: https://doi.org/10.1515/BC.2002.181.

Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Kashif Aziz Khan, Alain Coaquette, Christian Davrinche, and Georges Herbein
The Journal of Immunology, 2009, Volume 182, Number 12, Page 7784
[2]
[4]
Donna Collins-McMillen, Jason Buehler, Megan Peppenelli, and Felicia Goodrum
Viruses, 2018, Volume 10, Number 8, Page 444
[6]
Verity G. Kew, Jinxiang Yuan, Jeffery Meier, Matthew B. Reeves, and Eain Anthony Murphy
PLoS Pathogens, 2014, Volume 10, Number 6, Page e1004195
[7]
Liane Dupont and Matthew B. Reeves
Reviews in Medical Virology, 2016, Volume 26, Number 2, Page 75
[8]
T. E. Glover, V. G. Kew, and M. B. Reeves
Journal of General Virology, 2014, Volume 95, Number Pt_10, Page 2260
[9]
John Sinclair and Matthew Reeves
Frontiers in Microbiology, 2014, Volume 5
[10]
Matthew Reeves and John Sinclair
Viruses, 2013, Volume 5, Number 6, Page 1395
[11]
Jay A. Fishman
Seminars in Nephrology, 2007, Volume 27, Number 4, Page 445
[12]
Michael G. Ison and Jay A. Fishman
Clinics in Chest Medicine, 2005, Volume 26, Number 4, Page 691
[13]
Patrizia Caposio, Tiziana Musso, Anna Luganini, Hiroyasu Inoue, Marisa Gariglio, Santo Landolfo, and Giorgio Gribaudo
Antiviral Research, 2007, Volume 73, Number 3, Page 175
[14]
Thomas Efferth, Marta R. Romero, Dana G. Wolf, Thomas Stamminger, Jose J. G. Marin, and Manfred Marschall
Clinical Infectious Diseases, 2008, Volume 47, Number 6, Page 804
[15]
Jong-Seok Moon, Min-Young Lee, Sahng Wook Park, Woong Kyu Han, Soon-Won Hong, Jin-Hyun Ahn, and Kyung-Sup Kim
The Prostate, 2008, Volume 68, Number 13, Page 1450
[16]
Patrizia Caposio, Anna Luganini, Gabriele Hahn, Santo Landolfo, and Giorgio Gribaudo
Cellular Microbiology, 2007, Volume 9, Number 8, Page 2040
[17]
Alexandra Heininger and Klaus Hamprecht
Critical Care Medicine, 2006, Volume 34, Number 3, Page 929
[18]
Val�re J. Goossens, Maarten H.L. Christiaans, Marinus J. Blok, Peter H.W. Terporten, Peter Sillekens, Angela Lukacsi, Johannes P. Van Hooff, and Cathrien A. Bruggeman
Journal of Medical Virology, 2004, Volume 72, Number 1, Page 94

Comments (0)

Please log in or register to comment.
Log in